EUROACTION. A European Society of Cardiology Demonstration Project in Preventive Cardiology FINAL RESULTS

Similar documents
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

Models of preventive care in clinical practice to achieve 25 by 25

EUROACTION A model for secondary and primary preventive care to achieve 25 by 25

The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention

the high CVD risk smoker

Guidelines on cardiovascular risk assessment and management

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium

ASPIRE-2-PREVENT. Lifestyle and risk factor management and use of cardioprotective medication in coronary patients in the UK

Prevention in Europe

The 2012 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice


Guidelines for Integrated Management of. Cardiovascular Diseases and Diabetes. in Clinics and Ri-hospitals

Cardiovascular disease - from management to prevention

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Cardiac rehabilitation for coronary patients: lifestyle, risk factor and therapeutic management. Results from the EUROASPIRE II survey

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE

Depok-Indonesia STEPS Survey 2003

Kornelia Kotseva 1,2 David Wood 1 and Dirk De Bacquer 2 ;on behalf of EUROASPIRE investigators. Introduction. Full research paper

How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria versus

Professor Norman Sharpe. Heart Foundation West Coast

The Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine

DECLARATION OF CONFLICT OF INTEREST. None

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Preventive Cardiology Scientific evidence

Life After A Heart Attack

ASSeSSing the risk of fatal cardiovascular disease

BEST PRACTICE MANAGEMENT: CARDIOVASCULAR RISKS

Hospital Authority Convention 2010 Presented by : Dr Cheng Ming Kin Medical Officer,Department of Medicine Tseung Kwan O Hospital

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Ischaemic Heart Disease

Is there a mechanism of interaction between hypertension and dyslipidaemia?

Risk Factors for Heart Disease

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Repeat ischaemic heart disease audit of primary care patients ( ): Comparisons by age, sex and ethnic group

Cardiovascular Disease Risk Factors:

CE: lavanya ED: soumen: Op: vp HJR: LWW_HJR_200433

Identification of subjects at high risk for cardiovascular disease

Total risk management of Cardiovascular diseases Nobuhiro Yamada

APPENDIX 2F Management of Cholesterol

5 YEARS OF POSITIVE PATIENT OUTCOMES A Report Prepared by the National Institute for Preventive Cardiology

The GUIDANCE study. Kamlesh Khunti University of Leicester, UK. on behalf of the GUIDANCE Study Group

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Diabetes Control and Complications in Public Hospitals in Malaysia

PLEASE REMEMBER TO BRING TO EACH APPOINTMENT

SCIENTIFIC STUDY REPORT

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Prevenzione cardiovascolare e cambiamento degli stili di vita. Gian Franco Gensini

5 YEARS OF POSITIVE PATIENT OUTCOMES A Report Prepared by the National Institute for Preventive Cardiology

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

SPECIALIST HEART CARE

THE CVD CHALLENGE IN NORTHERN IRELAND. Together we can save lives and reduce NHS pressures

2013 ESC Guidelines on Diabetes, Pre-diabetes and Cardiovascular Diseases Developed in Collaboration with EASD

Identification of patients with heart failure and PREserved systolic Function : an Epidemiologic Regional study

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Clinical Care Performance. Financial Year 2012 to 2018

D.O Midwestern Univ. Internal Medicine Cardiology Chief fellow Senior partner of a large cardiology group,

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

The Clinical Unmet need in the patient with Diabetes and ACS

Reducing risk in heart disease

Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)

Cardiovascular Risk Assessment and Management Making a Difference

Heart disease and stroke major health problems

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

MyAction Couple: Primary Prevention Case Study. Teresa Mackay, Rhian Houghton, Tim Grove

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Volume 2; Number 11 July 2008

Understanding the metabolic syndrome

Type 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.

Prof. Renata Cífková, MD, CSc.

Audit of cholesterol management among primary care patients in rural southern Italy

The role of physical activity in the prevention and management of hypertension and obesity

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

CVD Prevention, Who to Consider

Management of ischaemic heart disease in primary care: towards better practice

22. Cardiovascular disease

Cardiovascular Complications in Diabetes

Since 1980, obesity has more than doubled worldwide, and in 2008 over 1.5 billion adults aged 20 years were overweight.

Quality indicators for CVD prevention across Europe. Michel Wensing Senior researcher

Metabolic Syndrome Is A Key Determinant Of Coronary Microvascular Function In Patients With Stable Coronary Disease Undergoing PCI

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Trends and Variations in General Medical Services Indicators for Coronary Heart Disease: Analysis of QRESEARCH Data

overweight you are part of it!... Healthier, fitter, safer... Seafarers Health Information Programme ICSW S.H.I.P.

A cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease

SIGN 149 Risk estimation and the prevention of cardiovascular disease. Quick Reference Guide July Evidence

Cardiovascular Disease in Women -Vive La Difference? Dr Homeyra Douglas Consultant Cardiologist Aintree University Hospital

Incorporating KT Concepts within Clinical Trials

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Using the New Hypertension Guidelines

Improvement on Outcomes of Overweight Type 2 Diabetics after an Enhanced Disease Management Programme

Latest Nutritional Guidelines: What s new for practice? Paul Pipe-Thomas Specialist Dietitian

LIST OF ABBREVIATIONS

PRESENTED BY BECKY BLAAUW OCT 2011

Vascular Diseases. Overview: Selected Slides

Understanding Cholesterol and Triglycerides

EuroPrevent 2010 Fatal versus total events in risk assessment models

Transcription:

EUROACTION A European Society of Cardiology Demonstration Project in Preventive Cardiology FINAL RESULTS Professor David Wood on behalf of the EUROACTION Group

EUROACTION 8 countries 24 centres 962 subjects

A CLUSTER RANDOMISED CONTROLLED TRIAL Randomisation INT UC Identification 2951 PATIENTS 1633 PARTNERS 2846 PATIENTS 1632 PARTNERS Initial assessment 2179 PATIENTS 898 PARTNERS 638 SUB-SAMPLE SAMPLE PROGRAMME 16 week hospital 1 year primary care One year assessment 1965 PATIENTS 626 PARTNERS 1999 PATIENTS 698 PARTNERS

EUROACTION Subjects Hospital programme Coronary patients & families ACS and stable angina pectoris General practice programme High risk patients & families SCORE 5% over years Treated hypertension or dyslipidaemia Diabetes mellitus

EUROACTION Primary endpoints Proportions of patients and families achieving lifestyle, risk factor and therapeutic targets for cardiovascular disease prevention Lifestyle management: smoking (breath CO), diet, physical activity Other risk factor management: Overweight/ obesity (BMI, waist circumference) Blood pressure Total cholesterol and LDL cholesterol Diabetes Cardioprotective drug therapies: anti-platelet, beta-blockers, ACE inhibitors/arb s, lipid lowering drugs

SMOKING Goal: ZERO

PATIENTS 7 6 5 3 Hospital Smoking cessation at one year in coronary patients who were smokers* + % ( -.3% to + 21%) 58 p =.6 47 *Smoking in month prior to index event 9 8 7 6 5 3 General Practice Non-smoking at one year in high risk patients +.8% (-( 13% to + 15%) 74 p =.9 72

DIET GOALS: Saturated fat: <% total energy Fruit and vegetables: g/day Fish: g/day Oily fish: 3 times/week

Proportions of patients achieving the European targets for a healthy diet Hospital General Practice 9 8 7 6 5 3 p =.9 55 Saturated fat < % of total energy p =.4 p =.62 72 35 Fruits and vegetables > g/day 79 67 p =.4 16 Fish > g/day Oily fish > 3 times/week 8 9 8 7 6 5 3 p =.5 78 39 Fruits and vegetables > g/day p =.7 83 67 p =.13 11 Fish > g/day Oily fish > 3 times/week 6

9 8 7 6 5 3 p =.31 6 42 Saturated fat < % of total energy Proportions of partners achieving the European targets for a healthy diet Hospital p =.2 72 37 Fruits and vegetables > g/day p =.68 78 63 p =.71 11 Fish > g/day Oily fish > 3 times/week 8 9 8 7 6 5 3 p =.2 77 54 Fruits and vegetables > g/day General Practice p =.46 81 66 p =.5 Fish > g/day Oily fish > 3 times/week 7

PHYSICAL ACTIVITY Goal: 3-45 minutes of physical activity at 6 75% of the average maximum heart rate on four-five five days of the week

Proportion of patients achieving European Guidelines for physical activity Hospital General Practice 6 + 36% (+% to + 51%) 6 + 29% ( + 11% to + 48%) 5 54 5 5 3 3 22 P =.2 P =.1

Caspersen and Powell physical activity classification in patients Hospital General Practice % 6 5 73 P=.4 56 % 6 5 72 P=.9 5 46 46 5 3 3 35 37 14 26 12 18 27 22 15 13 15 13 Sedentary Irregularly Regularly active Regularly active Sedentary Irregularly Regularly active Regularly active active not intensive intensive active not intensive intensive

5 Proportion of partners achieving European Guidelines for physical activity Hospital + 19% (-(.6% to + 38%) 5 General Practice + 27% (+ 4% to + 5%) 3 41 3 44 27 25 P =.6 p =.3

WEIGHT AND SHAPE Goals: BMI <25 kg/m² WAIST <94cm men <8cm women

Proportion of patients+ achieving 5% weight reduction Hospital + 6% (-( 7% to + 19%) General Practice + % (+5% to + 16%) 19 16 13 7 P =.28* p =.5* + Patients with a BMI 25 kg/m2 Sub-sample

Proportion of patients achieving the ideal waist circumference Hospital + 9% (-( 3% to + %) General Practice + 8% (-( 2% to + 18%) 3 31 3 22 23 15 p =.11 p =.

RISK FACTOR MANAGEMENT Goals: Blood pressure <1/9 mmhg (<13/85 mmhg in diabetes) Total cholesterol <5 mmol/l LDL cholesterol <3 mmol/l Diabetes: good glycaemic control

7 6 5 3 65 Proportion of patients achieving the European target for blood pressure Hospital + % (+.6% to + %) 55 7 6 5 3 General Practice 58 + 17% (+ 2% to + 32%) 41 P =.4 p =.3

Proportion of patients achieving the European lipid targets 9 8 7 6 5 3 Hospital TC + 7% ( -6% to + 19%) LDL-C C + 7% (.9% to + 15%) P=.23 81 78 74 71 TC < 5 mmol/l P=.7 LDL-C < 3 mmol/l 9 8 7 6 5 3 General Practice 36 32 TC < 5 mmol/l 45 35 LDL-C < 3 mmol/l

Change in proportion of high risk patients achieving the European lipid targets Total cholesterol LDL cholesterol 5 5 3 22 IA 36 1 YR 32 IA 32 1 YR 3 26 IA 44 1 YR 36 IA 36 1 YR IA = initial assessment 1 YR = one year assessment

Change in proportion of high risk patients achieving the European lipid targets Total cholesterol LDL cholesterol 5 45 35 3 25 15 5 22 IA 36 1 YR 32 IA 32 1 YR IA = initial assessment 1 YR = one year assessment 5 45 35 3 25 15 5 26 IA 44 1 YR 36 IA 36 1 YR

5 45 35 3 25 15 5 22 IA Change in proportion of high risk patients achieving the European lipid targets Total cholesterol 36 1 YR 32 IA 32 1 YR LDL cholesterol + 13% (+ 2% to + 23%) p =.25 + 17% (+ 7% to + 27%) p =.8 +18% +14% -.5% -% IA = initial assessment 1 YR = one year assessment 5 45 35 3 25 15 5 26 IA 44 1 YR 36 IA 36 1 YR

9 8 7 6 5 3 Proportion of patients with self- reported diabetes mellitus which is controlled (HbA1c <7%) Hospital + 11% (-13%( to +34%) General Practice + 12% (-( 5% to + 29%) 9 8 7 8 6 65 61 5 5 3 p =.29 p =.12

% 5 Hospital Distribution of HbA1c in patients with diabetes % 5 General Practice 3 36 3 42 37 21 24 29 23 21 17 29 25 12 15 9 < 6% 6-6.9% 7-7.9% >=8% < 6% 6-6.9% 7-7.9% >=8% HbA1c HbA1c

CARDIOPROTECTIVE DRUG THERAPIES

Hospital Proportion of patients on cardiovascular protective drug therapy General Practice p=.28 9 8 7 6 5 3 93 92 Anti-platelet drugs p=.16 76 8 Beta blockers p=.26 52 56 ACE inhibitors p=.53 21 19 Ca antagonists p=.4 86 8 Statins 9 8 7 6 5 3.19 13 Antiplatelet drugs p=.6 33 18 p=.91 17 16 p=.2 29 Diuretics B-blockers ACE CA Statins p=.24 9 8 p=.3 38 22

o o o LIMITATIONS Statistical power Statistical power was reduced because of patient numbers and heterogeneity in the differences between intervention and usual care between countries Under estimation o Usual care was being audited One quarter of usual care patients were clinically assessed at baseline One fifth of patients in usual care received cardiac rehabilitation o Over estimation Selective drop out - patients in intervention did not attend at one year

CONCLUSIONS

Conclusions EUROACTION has achieved its overall aim by raising standards of preventive cardiology care for coronary and high risk patients and their families in everyday clinical practice.

Conclusions The nurse-led multidisciplinary EUROACTION family based programme achieved significantly better lifestyle changes for coronary and high risk patients and partners in terms of a more healthy diet, and increased physical activity, compared to usual care

Conclusions The EUROACTION programme improved coronary and high risk patients: blood pressure control compared to usual care blood lipid control compared to usual care blood glucose control in patients with diabetes mellitus

Conclusions The EUROACTION programme increased prescribing for statins in coronary patients and for ACE inhibitors and statins in high risk people compared to usual care

Conclusions EUROACTION has set new standards of preventive cardiology care for coronary and high risk patients and their families in everyday clinical practice

EUROACTION Steering Group Professor Guy de Backer, Professor Dirk De Bacquer, Professor Martin Buxton, Professor Ian Graham, Mr Alan Howard, Dr Kornelia Kotseva, Ms Susanne Logstrup, Professor Hannah McGee, Ms Muriel Mioulet, Dr Karen Smith, Professor David Thompson, Professor David Wood National Co-ordinators & Primary Care Leaders

EUROACTION Steering Group National Co-ordinators ordinators and Primary Care Leads Dr Troels Thomsen (National co-ordinator) Dr Kim Brockelmann (Primary Care leader) Denmark Dr Catherine Monpere (National co-ordinator) France Professor Paolo Fioretti (National co-ordinator) Dr Alessandro Desideri (Deputy Co-ordinator) Professor Silvio Brusaferro (Primary Care leader) Italy Professor Andrzej Pajak (National coordinator) Dr Piotr Jankowski (Deputy Co-ordinator) Professor Tomasz Grodzicki (Primary Care leader) Poland Professor Jose de Velasco (National co-ordinator) Dr Antonio Maiques (Primary Care leader) Spain Professor Joep Perk (National co-ordinator) Sweden Assoc. Professor Trudy van der Weijden (Primary Care leader) The Netherlands Professor David Wood (National co-ordinator) Dr Jonathan Morrell (Primary Care leader) United Kingdom

EUROACTION Co-ordinating ordinating and Data Management Centre Cardiovascular Medicine, National Heart and Lung Institute, Medical Faculty, Imperial College, London, UK Dr Kornelia Kotseva (senior clinical research fellow) Dr Susan Connolly (consultant cardiologist) Ms Catriona Jennings (study nurse co-ordinator) Ms Alison Mead (chief dietician) Ms Jennifer Jones (superintendent physiotherapist) Ms Annie Holden (physical activity specialist) Mr Kamal Pandya (data manager) Ms Sally Graves (research administrator) Professor Ole Faergeman Professor David Wood (Chairman) Statistical Centre Department of Public Health, Ghent University, Ghent, Belgium Professor Dirk De Bacquer, Professor Guy De Backer (Chairman) Laboratory Centre Department of Pathological Biochemistry, Royal Infirmary, Glasgow, Scotland Professor Jim Shephard (Chairman)

EUROACTION A European Society of Cardiology demonstration project in preventive cardiology solely sponsored by an unconditional educational grant from Astra Zeneca www.escardio.org/euroaction